BioSpace News Archive

Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”) today announced financial results for its first quarter ended March 31, 2023, and provided a corporate update.

Harrow, a leading U.S. eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2023.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the first quarter ended March 31, 2023.

Aytu BioPharma, Inc. (the Company or “Aytu”) (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced financial and operational results for the quarter ended March 31, 2023.

Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) (“Dermata,” or the “Company”), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today highlighted recent corporate progress, and reported financial results for the first quarter ended March 31, 2023.

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, announced its cash position as of March 31, 2023 and revenues for the first three months of 20231.

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the first quarter ended March 31, 2023 and provided pipeline updates.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today reported its financial results for the three-month period ended March 31, 2023 and other recent developments.

Eliem Therapeutics, Inc. (Nasdaq: ELYM) today provided a business update and reported financial results for the quarter ended March 31, 2023.